Watch James Douglas discuss why he thinks healthcare’s focus has shifted from the US election to issues of affordability and access. James looks at why valuations for the drug & device makers and care providers remain attractive, explaining that the industry has strong fundamentals, news flow and corporate activity.
James Douglas, PhD
James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.
Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma.